{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:31Z","timestamp":1786979611438,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) ist eine chronisch-entz\u00fcndliche Erkrankung der oberen Atemwege mit starker Beeintr\u00e4chtigung der Lebensqualit\u00e4t. Die von \u201eNSAID-exacerbated respiratory disease\u201c (NERD) betroffenen Patienten weisen i.\u00a0d.\u00a0R. ein hochdynamisches Wiederauftreten der Beschwerden nach Operation, oraler Kortikosteroidgabe und Acetylsalicyls\u00e4uredesensibilisierung (ATAD) auf. Die Add-on-Biologikatherapie hat die Wahl des therapeutischen Konzepts grundlegend ver\u00e4ndert, Subgruppen wie der der NERD sind jedoch unzureichend untersucht. Ziel der vorliegenden Arbeit ist, es eine multizentrische retrospektive Studie \u00fcber die Add-on-Therapie mit Dupilumab, Omalizumab und Mepolizumab bei Patienten mit gesichertem NERD vorzustellen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methode<\/jats:title>\n                    <jats:p>Es handelt sich um eine retrospektive Kohortenstudie von Patienten (NERD+, Status nach ATAD) dreier Referenzzentren in Deutschland (M\u00fcnchen, Mainz, Berlin). Subjektive und objektive Parameter wurden nach 4\/8\/12\u00a0Monaten in \u00dcbereinstimmung mit EPOS\/EUFOREA-Richtlinien (European Position Paper on Rhinosinusitis and Nasal Polyps\/European Forum for Research and Education in Allergy and Airway Diseases) erhoben. Die Auswahl der Biologika erfolgte je nach Verf\u00fcgbarkeit und Patientencharakteristik.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Behandlungen wurden bei\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u2009122 Patienten mit CRSwNP und NERD begonnen. Der endoskopische Polypenscore, der SNOT-22-Fragebogen-Score (Sino-Nasal Outcome Test), der visuelle Analogskala-Score f\u00fcr die Gesamtsymptome\/Schwere der Erkrankung und der Geruchssinn (psychophysische Tests mit Sniffin\u2019Sticks\/Brief Smell Identification Test, B\u2011SIT, Fa.\u00a0Sensonics, Inc., Haddon Heights, NJ, USA) verbesserten sich signifikant nach 4\u00a0bzw. 12\u00a0Monaten Zusatztherapie (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,0001). Alle 3\u00a0Biologika f\u00fchrten zu einer signifikanten Verbesserung eines oder mehrerer Krankheitsparameter. Unerw\u00fcnschte Ereignisse waren nicht lebensbedrohlich, f\u00fchrten aber in 4\u00a0F\u00e4llen zu einem Wechsel des Biologikums. Die Patienten bewerteten die Biologikatherapie signifikant besser als ATAD, mit einer besseren langfristigen Kontrolle der Krankheit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die Add-on\u00a0Biologikatherapie ist wirksam, sicher und wird in der Gruppe der CRSwNP\u202f+\u2009NERD-Patienten weitgehend akzeptiert. K\u00fcnftige Studien k\u00f6nnten personalisierte Algorithmen mit sequenzieller Chirurgie, ATAD und\/oder Biologikatherapie erm\u00f6glichen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00106-024-01433-y","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T10:03:43Z","timestamp":1710151423000},"page":"473-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologikatherapie bei schwer erkrankten Patienten mit \u201eNSAID-exacerbated respiratory disease\u201c und stattgehabter ASS\u2011Desaktivierung","Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization"],"prefix":"10.1007","volume":"72","author":[{"given":"Anna-Rebekka","family":"Staufenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Frankenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"F\u00f6rster-Ruhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska C.","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Stihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Matthias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"9","key":"1433_CR1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","volume":"66","author":"D Hastan","year":"2011","unstructured":"Hastan\u00a0D, Fokkens\u00a0WJ, Bachert\u00a0C et\u00a0al (2011) Chronic rhinosinusitis in Europe\u2014an underestimated disease. A\u00a0GA(2)LEN study. Allergy 66(9):1216\u20131223. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02646.x","journal-title":"Allergy"},{"issue":"4","key":"1433_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4193\/Rhin11.252","volume":"50","author":"PW Hellings","year":"2012","unstructured":"Hellings\u00a0PW, Scadding\u00a0G, Alobid\u00a0I et\u00a0al (2012) Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology 50(4):339\u2013352. https:\/\/doi.org\/10.4193\/Rhin11.252","journal-title":"Rhinology"},{"issue":"6","key":"1433_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol\u00a0J, Azar\u00a0A, Buchheit\u00a0KM, Hopkins\u00a0C, Bernstein\u00a0JA (2022) Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era. J\u00a0Allergy Clin Immunol Pract 10(6):1434. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.002","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"1433_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/a-1197-0136","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, F\u00f6rster-Ruhrmann\u00a0U, Becker\u00a0S et\u00a0al (2020) Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen des \u00c4rzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). Laryngorhinootologie 99(8):511\u2013527. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"1433_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","volume":"68","author":"M Taniguchi","year":"2019","unstructured":"Taniguchi\u00a0M, Mitsui\u00a0C, Hayashi\u00a0H et\u00a0al (2019) Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. Allergol Int 68(3):289\u2013295. https:\/\/doi.org\/10.1016\/j.alit.2019.05.001","journal-title":"Allergol Int"},{"issue":"4","key":"1433_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.iac.2016.06.004","volume":"36","author":"WW Stevens","year":"2016","unstructured":"Stevens\u00a0WW, Schleimer\u00a0RP (2016) Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis. Immunol Allergy Clin North Am 36(4):669\u2013680. https:\/\/doi.org\/10.1016\/j.iac.2016.06.004","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"1433_CR7","first-page":"506","volume":"51","author":"T Mewes","year":"1996","unstructured":"Mewes\u00a0T, Riechelmann\u00a0H, Klimek\u00a0L (1996) Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance. Allergy 51(7):506\u2013510","journal-title":"Allergy."},{"issue":"5949","key":"1433_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/bmj.1.5949.67","volume":"1","author":"A Szczeklik","year":"1975","unstructured":"Szczeklik\u00a0A, Gryglewski\u00a0RJ, Czerniawskamysik\u00a0G (1975) Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1(5949):67\u201369. https:\/\/doi.org\/10.1136\/bmj.1.5949.67","journal-title":"BMJ"},{"issue":"1","key":"1433_CR9","first-page":"53","volume":"79","author":"W Hosemann","year":"2000","unstructured":"Hosemann\u00a0W, Kuhnel\u00a0T, Pfeifer\u00a0M (2000) Analgesic intolerance and nasal polyps. Laryngorhinootologie 79(1):53\u201365 (Analgetikaintoleranz und Polyposis nasi)","journal-title":"Laryngorhinootologie"},{"issue":"23","key":"1433_CR10","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1056\/NEJMc1813469","volume":"379","author":"AA White","year":"2018","unstructured":"White\u00a0AA, Stevenson\u00a0DD (2018) Aspirin-exacerbated respiratory disease. N\u00a0Engl J Med 379(23):2281\u20132282. https:\/\/doi.org\/10.1056\/NEJMc1813469","journal-title":"N Engl J Med"},{"issue":"3","key":"1433_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","volume":"5","author":"TM Laidlaw","year":"2017","unstructured":"Laidlaw\u00a0TM, Cahill\u00a0KN (2017) Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J\u00a0Allergy Clin Immunol Pract 5(3):537\u2013545. https:\/\/doi.org\/10.1016\/j.jaip.2016.10.021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1433_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/all.12131","volume":"68","author":"K Fruth","year":"2013","unstructured":"Fruth\u00a0K, Pogorzelski\u00a0B, Schmidtmann\u00a0I et\u00a0al (2013) Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 68(5):659\u2013665. https:\/\/doi.org\/10.1111\/all.12131","journal-title":"Allergy"},{"issue":"4","key":"1433_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/s0091-6749(96)70123-9","volume":"98","author":"DD Stevenson","year":"1996","unstructured":"Stevenson\u00a0DD, Hankammer\u00a0MA, Mathison\u00a0DA, Christiansen\u00a0SC, Simon\u00a0RA (1996) Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J\u00a0Allergy Clin Immunol 98(4):751\u2013758. https:\/\/doi.org\/10.1016\/s0091-6749(96)70123-9","journal-title":"J Allergy Clin Immunol"},{"issue":"40","key":"1433_CR14","doi-asserted-by":"publisher","first-page":"e27471","DOI":"10.1097\/MD.0000000000027471","volume":"100","author":"M Bertlich","year":"2021","unstructured":"Bertlich\u00a0M, Ihler\u00a0F, Bertlich\u00a0I, Weiss\u00a0BG, Groger\u00a0M, Haubner\u00a0F (2021) Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab. Medicine 100(40):e27471. https:\/\/doi.org\/10.1097\/MD.0000000000027471","journal-title":"Medicine"},{"issue":"10209","key":"1433_CR15","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert\u00a0C, Han\u00a0JK, Desrosiers\u00a0M et\u00a0al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase\u00a03\u00a0trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"3","key":"1433_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert\u00a0P, Omachi\u00a0TA, Corren\u00a0J et\u00a0al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase\u00a03\u00a0trials. J\u00a0Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1433_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han\u00a0JK, Bachert\u00a0C, Fokkens\u00a0W et\u00a0al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1433_CR18","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1111\/all.15507","volume":"77","author":"X Xu","year":"2022","unstructured":"Xu\u00a0X, Reitsma\u00a0S, Wang\u00a0Y, Fokkens\u00a0WJ (2022) Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. Allergy 77(12):3593\u20133605. https:\/\/doi.org\/10.1111\/all.15507","journal-title":"Allergy"},{"issue":"3","key":"1433_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4193\/Rhin19.318","volume":"58","author":"U Forster-Ruhrmann","year":"2020","unstructured":"Forster-Ruhrmann\u00a0U, Stergioudi\u00a0D, Pierchalla\u00a0G, Fluhr\u00a0JW, Bergmann\u00a0KC, Olze\u00a0H (2020) Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology 58(3):226\u2013232. https:\/\/doi.org\/10.4193\/Rhin19.318","journal-title":"Rhinology"},{"key":"1433_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/JAA.S357393","volume":"16","author":"JF Maspero","year":"2023","unstructured":"Maspero\u00a0JF, Bachert\u00a0C, Martinez\u00a0FJ et\u00a0al (2023) Clinical efficacy among patients with chronic rhinosinusitis with nasal polyps and clinical features of obstructive lung disease: post hoc analysis of the phase\u00a0III SINUS-24 and SINUS-52 studies. J\u00a0Asthma Allergy 16:333\u2013342. https:\/\/doi.org\/10.2147\/JAA.S357393","journal-title":"J Asthma Allergy"},{"issue":"12","key":"1433_CR21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","volume":"201","author":"H Hayashi","year":"2020","unstructured":"Hayashi\u00a0H, Fukutomi\u00a0Y, Mitsui\u00a0C et\u00a0al (2020) Omalizumab for aspirin hypersensitivity and Leukotriene overproduction in aspirin-exacerbated respiratory disease. A\u00a0randomized controlled trial. Am J Respir Crit Care Med 201(12):1488\u20131498. https:\/\/doi.org\/10.1164\/rccm.201906-1215OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1433_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/all.15067","volume":"77","author":"J Mullol","year":"2022","unstructured":"Mullol\u00a0J, Laidlaw\u00a0TM, Bachert\u00a0C et\u00a0al (2022) Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a\u00a0clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase\u00a03\u00a0trials. Allergy 77(4):1231\u20131244. https:\/\/doi.org\/10.1111\/all.15067","journal-title":"Allergy"},{"issue":"6","key":"1433_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","volume":"126","author":"SS Mustafa","year":"2021","unstructured":"Mustafa\u00a0SS, Vadamalai\u00a0K (2021) Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 126(6):738\u2013739. https:\/\/doi.org\/10.1016\/j.anai.2021.03.010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1433_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/1945892420961969","volume":"35","author":"SS Mustafa","year":"2021","unstructured":"Mustafa\u00a0SS, Vadamalai\u00a0K, Scott\u00a0B, Ramsey\u00a0A (2021) Dupilumab as add-on therapy for chronic Rhinosinusitis with nasal Polyposis in aspirin exacerbated respiratory disease. Am J Rhinol Allergy 35(3):399\u2013407. https:\/\/doi.org\/10.1177\/1945892420961969","journal-title":"Am J Rhinol Allergy"},{"issue":"12","key":"1433_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/alr.22865","volume":"11","author":"M Yong","year":"2021","unstructured":"Yong\u00a0M, Wu\u00a0YQ, Howlett\u00a0J, Ballreich\u00a0J, Walgama\u00a0E, Thamboo\u00a0A (2021) Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 11(12):1626\u20131636. https:\/\/doi.org\/10.1002\/alr.22865","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"1433_CR26","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert\u00a0C, Sousa\u00a0AR, Han\u00a0JK et\u00a0al (2022) Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J\u00a0Allergy Clin Immunol 149(5):1711\u20131721. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.040","journal-title":"J Allergy Clin Immunol"},{"key":"1433_CR27","doi-asserted-by":"publisher","unstructured":"Pfaar O, Beule AG, Laudien M, Stuck BA, erweiterte Leitliniengruppe Biologika bei C. [Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM)]. HNO. Apr 2023;71(4):256\u2013263. Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antikorpern (Biologika): S2k-Leitlinie der Deutschen Gesellschaft fur Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) und der Deutschen Gesellschaft fur Allgemeinmedizin und Familienmedizin (DEGAM). https:\/\/doi.org\/10.1007\/s00106-023-01273-2","DOI":"10.1007\/s00106-023-01273-2"},{"issue":"3","key":"1433_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens\u00a0WJ, Viskens\u00a0AS, Backer\u00a0V et\u00a0al (2023) EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61(3):194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"issue":"12","key":"1433_CR29","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens\u00a0WJ, Lund\u00a0V, Bachert\u00a0C et\u00a0al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312\u20132319. https:\/\/doi.org\/10.1111\/all.13875","journal-title":"Allergy"},{"issue":"Suppl 29","key":"1433_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ, Lund\u00a0VJ, Hopkins\u00a0C et\u00a0al (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 58(Suppl 29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"issue":"5","key":"1433_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert\u00a0C, Mannent\u00a0L, Naclerio\u00a0RM et\u00a0al (2016) Effect of subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a\u00a0randomized clinical trial. JAMA 315(5):469\u2013479. https:\/\/doi.org\/10.1001\/jama.2015.19330","journal-title":"JAMA"},{"issue":"5","key":"1433_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins\u00a0C, Gillett\u00a0S, Slack\u00a0R, Lund\u00a0VJ, Browne\u00a0JP (2009) Psychometric validity of the 22-item Sinonasal outcome test. Clin Otolaryngol 34(5):447\u2013454. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x","journal-title":"Clin Otolaryngol"},{"issue":"4","key":"1433_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00106-019-0614-x","volume":"67","author":"M Damm","year":"2019","unstructured":"Damm\u00a0M, Schmitl\u00a0L, M\u00fcller\u00a0CA, Welge-L\u00fcssen\u00a0A, Hummel\u00a0T (2019) Diagnostik und Therapie von Riechst\u00f6rungen. Diagnostics and treatment of olfactory dysfunction. HNO 67(4):274\u2013281. https:\/\/doi.org\/10.1007\/s00106-019-0614-x","journal-title":"HNO"},{"key":"1433_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/all.15796","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans\u00a0RJL, Otten\u00a0JJ, Adriaensen\u00a0G et\u00a0al (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6\u00a0months. Allergy. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"},{"issue":"5","key":"1433_CR35","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","volume":"16","author":"T Albrecht","year":"2023","unstructured":"Albrecht\u00a0T, Sailer\u00a0MM, Capitani\u00a0F, van Schaik\u00a0C, Lowenheim\u00a0H, Becker\u00a0S (2023) Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1\u00a0year of therapy. World Allergy Organ\u00a0J 16(5):100780. https:\/\/doi.org\/10.1016\/j.waojou.2023.100780","journal-title":"World Allergy Organ J"},{"issue":"2","key":"1433_CR36","doi-asserted-by":"publisher","first-page":"E324","DOI":"10.1002\/lary.28698","volume":"131","author":"A Yoshino","year":"2021","unstructured":"Yoshino\u00a0A, Goektas\u00a0G, Mahmut\u00a0MK et\u00a0al (2021) A\u00a0new method for assessment of retronasal olfactory function. Laryngoscope 131(2):E324\u2013E330. https:\/\/doi.org\/10.1002\/lary.28698","journal-title":"Laryngoscope"},{"issue":"7","key":"1433_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3109\/00016489.2012.656764","volume":"132","author":"S Becker","year":"2012","unstructured":"Becker\u00a0S, Pflugbeil\u00a0C, Groger\u00a0M, Canis\u00a0M, Ledderose\u00a0GJ, Kramer\u00a0MF (2012) Olfactory dysfunction in seasonal and perennial allergic rhinitis. Acta Otolaryngol 132(7):763\u2013768. https:\/\/doi.org\/10.3109\/00016489.2012.656764","journal-title":"Acta Otolaryngol"},{"key":"1433_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.403","volume-title":"Interleukin-4 directly activates olfactory neurons and induces loss of smell in mice","author":"YMKJ Hara","year":"2023","unstructured":"Hara\u00a0YMKJ, Mattoo\u00a0H, Nash\u00a0S, Khan\u00a0A, Orengo\u00a0JM, Hicks\u00a0A (2023) Interleukin\u20114 directly activates olfactory neurons and induces loss of smell in mice. American Academy of Allergy, Asthma & Immunology (AAAAI) Poster Abstract."},{"issue":"8","key":"1433_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","volume":"19","author":"J Otten","year":"2023","unstructured":"Otten\u00a0J, van der Lans\u00a0R, de Corso\u00a0E et\u00a0al (2023) Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol 19(8):1041\u20131049. https:\/\/doi.org\/10.1080\/1744666X.2023.2218617","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1433_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1067\/mai.2003.7","volume":"111","author":"MP Berges-Gimeno","year":"2003","unstructured":"Berges-Gimeno\u00a0MP, Simon\u00a0RA, Stevenson\u00a0DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J\u00a0Allergy Clin Immunol 111(1):180\u2013186. https:\/\/doi.org\/10.1067\/mai.2003.7","journal-title":"J Allergy Clin Immunol"},{"issue":"1 Pt 1","key":"1433_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0091-6749(90)90222-p","volume":"85","author":"JM Sweet","year":"1990","unstructured":"Sweet\u00a0JM, Stevenson\u00a0DD, Simon\u00a0RA, Mathison\u00a0DA (1990) Long-term effects of aspirin desensitization\u2014treatment for aspirin-sensitive rhinosinusitis-asthma. J\u00a0Allergy Clin Immunol 85(1 Pt 1):59\u201365. https:\/\/doi.org\/10.1016\/0091-6749(90)90222-p","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1433_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jaci.2006.09.011","volume":"119","author":"JY Lee","year":"2007","unstructured":"Lee\u00a0JY, Simon\u00a0RA, Stevenson\u00a0DD (2007) Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J\u00a0Allergy Clin Immunol 119(1):157\u2013164. https:\/\/doi.org\/10.1016\/j.jaci.2006.09.011","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1433_CR43","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1111\/all.14964","volume":"76","author":"M Lommatzsch","year":"2021","unstructured":"Lommatzsch\u00a0M, Stoll\u00a0P, Winkler\u00a0J et\u00a0al (2021) Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy 76(9):2920\u20132923. https:\/\/doi.org\/10.1111\/all.14964","journal-title":"Allergy"},{"issue":"11","key":"1433_CR44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/alr.21377","volume":"4","author":"RM Leung","year":"2014","unstructured":"Leung\u00a0RM, Dinnie\u00a0K, Smith\u00a0TL (2014) When do the risks of repeated courses of corticosteroids exceed the risks of surgery? Int Forum Allergy Rhinol 4(11):871\u2013876. https:\/\/doi.org\/10.1002\/alr.21377","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"1433_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4193\/Rhin22.129","volume":"60","author":"BR Haxel","year":"2022","unstructured":"Haxel\u00a0BR, Hummel\u00a0T, Fruth\u00a0K et\u00a0al (2022) Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology 60(6):435\u2013443. https:\/\/doi.org\/10.4193\/Rhin22.129","journal-title":"Rhinology"},{"issue":"2","key":"1433_CR46","doi-asserted-by":"publisher","first-page":"Ab56","DOI":"10.1016\/j.jaci.2020.12.226","volume":"147","author":"H Hayashi","year":"2021","unstructured":"Hayashi\u00a0H, Fukutomi\u00a0Y, Mitsui\u00a0C et\u00a0al (2021) Efficacy of omalizumab against aspirin-hypersensitivity and overproduction of cysteinyl leukotrienes in aspirin-exacerbated respiratory disease: a\u00a0randomized trial. J\u00a0Allergy Clin Immunol 147(2):Ab56\u2013Ab56","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1433_CR47","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","volume":"149","author":"P Oykhman","year":"2022","unstructured":"Oykhman\u00a0P, Paramo\u00a0FA, Bousquet\u00a0J, Kennedy\u00a0DW, Brignardello-Petersen\u00a0R, Chu\u00a0DK (2022) Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a\u00a0systematic review and network meta-analysis. J\u00a0Allergy Clin Immunol 149(4):1286\u20131295. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1433_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","volume":"10","author":"H Wangberg","year":"2022","unstructured":"Wangberg\u00a0H, Spierling Bagsic\u00a0SR, Osuna\u00a0L, White\u00a0AA (2022) Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease. J\u00a0Allergy Clin Immunol Pract 10(2):478\u2013484 e3. https:\/\/doi.org\/10.1016\/j.jaip.2021.09.030","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-024-01433-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T08:02:07Z","timestamp":1718956927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-024-01433-y"}},"subtitle":["Ergebnisse einer multizentrischen Studie","Results of a multicentric study"],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s00106-024-01433-y","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"22 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Gr\u00f6ger, L.\u00a0Klimek und J.\u00a0Hagemann geben Honorare und beratende Funktionen von Sanofi, GSK and Novartis an (au\u00dferhalb der hier eingereichten Arbeit). K.\u00a0Fruth gibt Honorare von Sanofi an (au\u00dferhalb der hier eingereichten Arbeit). A.-R.\u00a0Staufenberg, H.K.\u00a0Frankenberger, U.\u00a0F\u00f6rster-Ruhrmann, F.C.\u00a0Spahn, C.\u00a0Stihl und C.\u00a0Matthiasgeben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}